Glucagon-Like Peptide-1 (GLP-1) Receptors Expressed on Nerve Terminals in the Portal Vein Mediate the Effects of Endogenous GLP-1 on Glucose Tolerance in Rats
The DOI matches its Crossref record; 51 of the 57 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 (GLP-1) is an intestinal hormone that is secreted during meal absorption and is essential for normal glucose homeostasis. However, the relatively low plasma levels and rapid metabolism of GLP-1 raise questions as to whether direct endocrine action on target organs, such as islet cells, account for all of its effects on glucose tolerance. Recently, an alternative neural pathway initiated by sensors in the hepatic portal region has been proposed to mediate GLP-1 activity. We hypothesized that visceral afferent neurons in the portal bed express the GLP-1 receptor (GLP-1r) and regulate glucose tolerance. Consistent with this hypothesis, GLP-1r mRNA was present in the nodose ganglia, and nerve terminals innervating the portal vein contained the GLP-1r. Rats given an intraportal infusion of the GLP-1r antagonist, [des-His(1),Glu(9)] exendin-4, in a low dose, had glucose intolerance, with a 53% higher glucose excursion compared with a vehicle-infused control group. Infusion of [des-His(1),Glu(9)] exendin-4 at an identical rate into the jugular vein had no effect on glucose tolerance, demonstrating that this dose of GLP-1r antagonist did not affect blood glucose due to spillover into the systemic circulation. These studies demonstrate that GLP-1r are present on nerve terminals in the hepatic portal bed and that GLP-1 antagonism localized to this region impairs glucose tolerance. These data are consistent with an important component of neural mediation of GLP-1 action.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GLP-1 receptor was found in nerves that innervate hepatocytes [172], but their presence on human liver or hepatocytes is debated as found by some [169,170] but not others [173,174].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [172]
Citations
Cites
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Kieffer, T. J., & Francis Habener, J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,062
Thorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906
Vilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884
Deacon, C. F., Nauck, M. A., Toft-Nielsen, M., Pridal, L., Willms, B., & Holst, J. J. (1995) · Diabetes · doi:10.2337/diab.44.9.1126 · Cited by 878
Hansen, L., Deacon, C. F., Ørskov, C., & Holst, J. J. (1999) · Endocrinology · doi:10.1210/endo.140.11.7143 · Cited by 595
Enhancing Incretin Action for the Treatment of Type 2 Diabetes
Drucker, D. J. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2929 · Cited by 579
Nauck, M. A. (1993) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.76.4.912 · Cited by 506
Cited by
Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
“Glp1rmRNA transcripts have been identified in the rat nodose ganglion, which contains vagal afferent nerves, and an immunoreactive GLP-1R protein was detected by western blotting and immunohistochemistry in the portal vein (Vahl et al., 2007).”
BackgroundPhysiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease
Sandoval, D. A., & D'Alessio, D. A. (2015) · Physiological Reviews · doi:10.1152/physrev.00013.2014 · Cited by 498
Self-citationRichards, P., Parker, H. E., Adriaenssens, A. E., Hodgson, J. M., Cork, S. C., Trapp, S., Gribble, F. M., & Reimann, F. (2014) · Diabetes · doi:10.2337/db13-1440 · Cited by 472
“That GLP-1 activates vagal afferent neurons terminating in the wall of the portal vein has been recognized for several years (10).”
BackgroundZhou, J., Martin, R. J., Tulley, R. T., Raggio, A. M., McCutcheon, K. L., Shen, L., Danna, S. C., Tripathy, S., Hegsted, M., & Keenan, M. J. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90637.2008 · Cited by 460
Central Control of Body Weight and Appetite
Woods, S. C., & D'Alessio, D. A. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1630 · Cited by 458
Self-citationNauck, M. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12591 · Cited by 429
“This relatively strong clinical effectiveness of DPP-4 inhibitors relative to the GLP-1 plasma concentrations achieved may be related to the differential distribution patterns of activated GLP-1Rs by DPP-4 inhibitors compared with that induced by GLP-1RAs.”
BackgroundInfluentialSvegliati‐Baroni, G., Saccomanno, S., Rychlicki, C., Agostinelli, L., De Minicis, S., Candelaresi, C., Faraci, G., Pacetti, D., Vivarelli, M., Nicolini, D., et al. (2011) · Liver International · doi:10.1111/j.1478-3231.2011.02462.x · Cited by 405
Neuronal GLP1R mediates liraglutide’s anorectic but not glucose-lowering effect
Sisley, S., Gutierrez-Aguilar, R., Scott, M., D’Alessio, D. A., Sandoval, D. A., & Seeley, R. J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72434 · Cited by 397
“The portal vein, which is innervated by the nodose ganglia and robustly expresses GLP1R, has also been hypothesized to contribute to endogenous GLP1’s actions (13).”
InfluentialSelf-citationNauck, M. A., Quast, D. R., Wefers, J., & Pfeiffer, A. F. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14496 · Cited by 388
Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS
van Bloemendaal, L., ten Kulve, J. S., la Fleur, S. E., Ijzerman, R. G., & Diamant, M. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0414 · Cited by 312
“Because GLP-1 receptors have been observed on vagal fibres (Vahl et al. 2007), it has been suggested that the vagal nerve plays an important role in the communication between gut and brain.”
Evidence that Intestinal Glucagon-Like Peptide-1 Plays a Physiological Role in Satiety
Williams, D. L., Baskin, D. G., & Schwartz, M. W. (2009) · Endocrinology · doi:10.1210/en.2008-1045 · Cited by 300
“GLP-1’s incretin effects have been hypothesized to occur via a local action on afferent autonomic fibers in the gut and/or hepatic portal vein, as opposed to a direct action on -cells (33).”
BackgroundGLP-1 and weight loss: unraveling the diverse neural circuitry
Kanoski, S. E., Hayes, M. R., & Skibicka, K. P. (2016) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00520.2015 · Cited by 290
Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation
McLean, B. A., Wong, C. K., Campbell, J. E., Hodson, D. J., Trapp, S., & Drucker, D. J. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnaa032 · Cited by 289
“GLP-1Rs are expressed by sets of vagal afferent neurons (35, 131, 132), which are”
BackgroundRegulation of Glucose Homeostasis by GLP-1
Nadkarni, P., Chepurny, O. G., & Holz, G. G. (2014) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-800101-1.00002-8 · Cited by 287
Bile acid signaling pathways from the enterohepatic circulation to the central nervous system
Mertens, K. L., Kalsbeek, A., Soeters, M. R., & Eggink, H. M. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00617 · Cited by 287
“GLP-1 signaling via vagal afferents in the hepatic portal vein does not modulate food intake (Rüttimann et al., 2009), but is involved in modulating glucose metabolism by interacting with hepatoportal glucose sensors (Balkan and Li, 2000; Burcelin et al., 2001; Vahl et al., 2007).”
BackgroundRole of the gut-brain axis in energy and glucose metabolism
Wachsmuth, H. R., Weninger, S. N., & Duca, F. A. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00677-w · Cited by 269
Knockdown of GLP-1 Receptors in Vagal Afferents Affects Normal Food Intake and Glycemia
Krieger, J.-P., Arnold, M., Pettersen, K. G., Lossel, P., Langhans, W., & Lee, S. J. (2016) · Diabetes · doi:10.2337/db15-0973 · Cited by 269
Bauer, P. V., Duca, F. A., Waise, T. M. Z., Rasmussen, B. A., Abraham, M. A., Dranse, H. J., Puri, A., O’Brien, C. A., & Lam, T. K. T. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.09.019 · Cited by 265
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Liu, Q. K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1431292 · Cited by 265
Rüttimann, E. B., Arnold, M., Hillebrand, J. J., Geary, N., & Langhans, W. (2009) · Endocrinology · doi:10.1210/en.2008-1221 · Cited by 258
Gut chemosensing: Interactions between gut endocrine cells and visceral afferents
Raybould, H. E. (2010) · Autonomic Neuroscience · doi:10.1016/j.autneu.2009.07.007 · Cited by 254
“The cell bodies of vagal afferents express GLP-1 receptors and these terminate in the hepatic portal vein and infusion of low doses of GLP-1 receptor antagonist into the portal vein induced glucose intolerance in rats (Vahl et al, 2007).”
BackgroundG-Protein-Coupled Receptors in Intestinal Chemosensation
Reimann, F., Tolhurst, G., & Gribble, F. M. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2011.12.019 · Cited by 236
Jahan-Mihan, A., Luhovyy, B. L., El Khoury, D., & Anderson, G. H. (2011) · Nutrients · doi:10.3390/nu3050574 · Cited by 233
“expressed on vagal afferents and thereby regulates glucose homeostasis [93] and satiety [94].”
BackgroundThe role of the autonomic nervous liver innervation in the control of energy metabolism
Yi, C.-X., la Fleur, S. E., Fliers, E., & Kalsbeek, A. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.01.006 · Cited by 228
“Indeed, GLP-1 receptors are expressed in the hepatoportal area [145].”
BackgroundIncretin-Based Therapies in Type 2 Diabetes Mellitus
Chia, C. W., & Egan, J. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2109 · Cited by 223
GLP-1 and energy balance: an integrated model of short-term and long-term control
Barrera, J. G., Sandoval, D. A., D'Alessio, D. A., & Seeley, R. J. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.77 · Cited by 220
“In rats, GLP1R mRNA is expressed in cell bodies of the nodose ganglion”
Self-citationMetabolic messengers: glucagon-like peptide 1
Gribble, F. M., & Reimann, F. (2021) · Nature Metabolism · doi:10.1038/s42255-020-00327-x · Cited by 199
Verspohl, E. J. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.06.002 · Cited by 196
An inter-organ neural circuit for appetite suppression
Zhang, T., Perkins, M. H., Chang, H., Han, W., & de Araujo, I. E. (2022) · Cell · doi:10.1016/j.cell.2022.05.007 · Cited by 192
Deacon, C. F., Mannucci, E., & Ahrén, B. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01603.x · Cited by 190
“In support of this, the GLP-1 receptor has been reported to be expressed on neurons in the portal vein [42].”
BackgroundIncretin hormones and the satiation signal
Holst, J. J. (2013) · International Journal of Obesity · doi:10.1038/ijo.2012.208 · Cited by 188
Daly, D. M., Park, S. J., Valinsky, W. C., & Beyak, M. J. (2011) · The Journal of Physiology · doi:10.1113/jphysiol.2010.204594 · Cited by 188
Glucagon-like peptide 1 and appetite
Dailey, M. J., & Moran, T. H. (2013) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2012.11.008 · Cited by 186
“The major circulating bioactive species in humans is the truncated form GLP-1 (7-36) amide 2.”
BackgroundAhrén, B., Schweizer, A., Dejager, S., Dunning, B. E., Nilsson, P. M., Persson, M., & Foley, J. E. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2152 · Cited by 183
“This would be consistent with the growing body of literature suggesting that many of the actions often ascribed to circulating GLP-1 may in fact be mediated by neuronal mechanisms (23-28).”
ResultPlamboeck, A., Veedfald, S., Deacon, C. F., Hartmann, B., Wettergren, A., Svendsen, L. B., Meisner, S., Hovendal, C., Vilsbøll, T., Knop, F. K., et al. (2013) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00035.2013 · Cited by 183
Horowitz, M., Flint, A., Jones, K. L., Hindsberger, C., Rasmussen, M. F., Kapitza, C., Doran, S., Jax, T., Zdravkovic, M., & Chapman, I. M. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.02.016 · Cited by 179
“[42] Vahl TP, Tauchi M, Durler TS, et al.”
BackgroundThe Integrative Role of CNS Fuel-Sensing Mechanisms in Energy Balance and Glucose Regulation
Sandoval, D., Cota, D., & Seeley, R. J. (2008) · Annual Review of Physiology · doi:10.1146/annurev.physiol.70.120806.095256 · Cited by 178
Self-citationLiraglutide: short‐lived effect on gastric emptying—long lasting effects on body weight
Jelsing, J., Vrang, N., Hansen, G., Raun, K., Tang‐Christensen, M., & Bjerre Knudsen, L. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01557.x · Cited by 155
“GLP-1 receptors are expressed on the vagal afferents [26] and desensitization of these receptors may be responsible for the subsiding gastric inhibitory effects [22].”
BackgroundLamont, B. J., Li, Y., Kwan, E., Brown, T. J., Gaisano, H., & Drucker, D. J. (2012) · Journal of Clinical Investigation · doi:10.1172/jci42497 · Cited by 174
GLP-1 receptor signaling is not required for reduced body weight after RYGB in rodents
Ye, J., Hao, Z., Mumphrey, M. B., Townsend, R. L., Patterson, L. M., Stylopoulos, N., Münzberg, H., Morrison, C. D., Drucker, D. J., & Berthoud, H.-R. (2014) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00491.2013 · Cited by 174
Role of the glucagon-like-peptide-1 receptor in the control of energy balance
Hayes, M. R., De Jonghe, B. C., & Kanoski, S. E. (2010) · Physiology & Behavior · doi:10.1016/j.physbeh.2010.02.029 · Cited by 173
“Instead, the finding that intraportal infusion of a GLP-1R antagonist produces a hyperglycemic response following intragastric glucose infusion [34] suggests that for vagal afferent GLP-1R populations in the periphery, the control of glycemic responses may be dissociable from the food intake inhibitory responses.”
InfluentialGlucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes
Muscogiuri, G., DeFronzo, R. A., Gastaldelli, A., & Holst, J. J. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.10.001 · Cited by 171
Smith, E. P., An, Z., Wagner, C., Lewis, A. G., Cohen, E. B., Li, B., Mahbod, P., Sandoval, D., Perez-Tilve, D., Tamarina, N., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.04.005 · Cited by 164
“Finally, there is growing evidence that GLP-1 regulates glucose metabolism indirectly via GLP1R expressed on peripheral and central neurons (Donath and Burcelin, 2013; Vahl et al., 2007; Waget et al., 2011).”
BackgroundResultSelf-citationGlucagon Like Peptide-1 Receptor Expression in the Human Thyroid Gland
Gier, B., Butler, P. C., Lai, C. K., Kirakossian, D., DeNicola, M. M., & Yeh, M. W. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2407 · Cited by 157
“Validation of the antisera NLS1206 was also performed and published previously (11).”
BackgroundMolecular mechanisms underlying nutrient-stimulated incretin secretion
Parker, H. E., Reimann, F., & Gribble, F. M. (2010) · Expert Reviews in Molecular Medicine · doi:10.1017/s146239940900132x · Cited by 155
Trapp, S., & Brierley, D. I. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15638 · Cited by 154
“Currently, there is clear evidence that a subset of vagal afferents express GLP-1 receptors per se (Bai et al., 2019; Vahl et al., 2007; Williams et al., 2016), that PPG neurons receive both monosynaptic and polysynaptic inputs from vagal afferents (Hisadome et al., 2010) and that PPG neurons are…”
BackgroundWaget, A., Cabou, C., Masseboeuf, M., Cattan, P., Armanet, M., Karaca, M., Castel, J., Garret, C., Payros, G., Maida, A., et al. (2011) · Endocrinology · doi:10.1210/en.2011-0286 · Cited by 153
“GLP-1R mRNA has been localized to the nodose ganglia, and nerve terminals innervating the portal vein contained immunoreactive GLP-1R (45).”
BackgroundZhao, L., Chen, Y., Xia, F., Abudukerimu, B., Zhang, W., Guo, Y., Wang, N., & Lu, Y. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00233 · Cited by 153
“GLP-1 receptors are located on neurons innervating the portal vein (38), on β cells of the pancreas (39), in the central nervous system (40), and on vagal afferents that innervate the gut in proximity to L cells (41).”
Activation of Spinal Glucagon-Like Peptide-1 Receptors Specifically Suppresses Pain Hypersensitivity
Gong, N., Xiao, Q., Zhu, B., Zhang, C.-Y., Wang, Y.-C., Fan, H., Ma, A.-N., & Wang, Y.-X. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.4703-13.2014 · Cited by 147
“Primers were as follows: 5 -CCA AGG TCA TCC ATG ACA AC-3 ( gapdh forward), 5 -TCC ACA GTC TTC TGA GTG GC-3 ( gapdh reverse), 5 -ACG CAC TTT CTT TCT CTG CC-3 (GLP-1R forward), 5 -CAA ACA GGT TCA GGT GGA TG-3 (GLP-1R reverse) (Vahl et al., 2007).”
BackgroundMethodLiraglutide and obesity: a review of the data so far
Ladenheim, E. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s58459 · Cited by 146
Grunddal, K. V., Ratner, C. F., Svendsen, B., Sommer, F., Engelstoft, M. S., Madsen, A. N., Pedersen, J., Nøhr, M. K., Egerod, K. L., Nawrocki, A. R., et al. (2016) · Endocrinology · doi:10.1210/en.2015-1600 · Cited by 146
Direct effect of GLP-1 infusion on endogenous glucose production in humans
Seghieri, M., Rebelos, E., Gastaldelli, A., Astiarraga, B. D., Casolaro, A., Barsotti, E., Pocai, A., Nauck, M., Muscelli, E., & Ferrannini, E. (2013) · Diabetologia · doi:10.1007/s00125-012-2738-3 · Cited by 143
“GLP-1 receptor mRNA has also been described in neurons in the hepatic portal region [7].”
BackgroundThe metabolic role of vagal afferent innervation
Waise, T. M. Z., Dranse, H. J., & Lam, T. K. T. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0062-1 · Cited by 140
Nutritional modulation of endogenous glucagon-like peptide-1 secretion: a review
Bodnaruc, A. M., Prud’homme, D., Blanchet, R., & Giroux, I. (2016) · Nutrition & Metabolism · doi:10.1186/s12986-016-0153-3 · Cited by 139
“Indeed, GLP-1Rs have been identified on neurons of the nodose ganglion of the vagus nerve [43, 49], and the importance of this pathway in the regulation of food intake has been confirmed in rats, where vagal deafferentation decreased the effects of intraperitoneally administered GLP-1 [50, 51].”
BackgroundInsulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis
Tomas, E., & Habener, J. F. (2010) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2009.11.007 · Cited by 137
Diabetes medications and body weight
Mitri, J., & Hamdy, O. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330903081725 · Cited by 135
“However, this mechanism is debated as peripheral infusion of GLP-1 at concentrations similar to those resulting from DPP-4 inhibition did not improve glycemic control and raised the possibility that having GLP-1 peripherally may not produce the same glycemic effect as having the same concentration in the portal circul…”
BackgroundVrang, N., & Larsen, P. J. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.07.003 · Cited by 153
Microbial regulation of GLP-1 and L-cell biology
Greiner, T. U., & Bäckhed, F. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.05.012 · Cited by 131
“Thus, receptor activation could enable a neuronal signaling route mediating the incretin effect, which has experimental support [61,68].”
BackgroundUnraveling oxyntomodulin, GLP1's enigmatic brother
Pocai, A. (2012) · Journal of Endocrinology · doi:10.1530/joe-12-0368 · Cited by 130
“This observation raised concerns regarding the relevance of portal GLP1 or other peptide concentrations in regulating glucose homeostasis and other pharmacodynamic effects and represents a potential limitation in the majority of studies that rely only on measurement of systemic levels of native peptides (Vahl et al. 2…”
BackgroundPleiotropic Mechanisms for the Glucose-Lowering Action of DPP-4 Inhibitors
Omar, B., & Ahrén, B. (2014) · Diabetes · doi:10.2337/db14-0052 · Cited by 126
“The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1-38).”
BackgroundKabahizi, A., Wallace, B., Lieu, L., Chau, D., Dong, Y., Hwang, E., & Williams, K. W. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15682 · Cited by 126
“GLP-1 acts through a G-protein–coupled receptor expressed on pancreatic beta cells and neurons of the central and peripheral nervous system (Kanoski et al., 2011; Nakagawa et al., 2004; Paternoster & Falasca, 2018; Sandoval et al., 2008; Vahl et al., 2007).”
BackgroundEffect of endogenous GLP-1 on insulin secretion in type 2 diabetes
Salehi, M., Aulinger, B., Prigeon, R. L., & D'Alessio, D. A. (2010) · Diabetes · doi:10.2337/db09-1253 · Cited by 124
“IV glucose infusion at variable rates Exendin-(9-39) or saline infusion Saline Ex-9”
Self-citationRonveaux, C. C., Tomé, D., & Raybould, H. E. (2015) · The Journal of Nutrition · doi:10.3945/jn.114.206029 · Cited by 124
“Of interest, GLP-1Rs have been localized in the portal vein, and a blockade of these GLP-1Rs substantially impairs glucose tolerance in rodents (43).”
Wired on sugar: the role of the CNS in the regulation of glucose homeostasis
Grayson, B. E., Seeley, R. J., & Sandoval, D. A. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3409 · Cited by 124
Self-citationGenetic tracing of Nav1.8‐expressing vagal afferents in the mouse
Gautron, L., Sakata, I., Udit, S., Zigman, J. M., Wood, J. N., & Elmquist, J. K. (2011) · Journal of Comparative Neurology · doi:10.1002/cne.22667 · Cited by 119
Glucagon‐like peptide‐1 in the rat brain: Distribution of expression and functional implication
Gu, G., Roland, B., Tomaselli, K., Dolman, C. S., Lowe, C., & Heilig, J. S. (2013) · Journal of Comparative Neurology · doi:10.1002/cne.23282 · Cited by 119
“Expression of glp-1r mRNA was found in neurons of the nodose ganglion of the vagus nerve and GLP-1 receptor immunoreactivity was observed in nerve terminals in the rat hepatic portal vein (Nakagawa et al., 2004; Vahl et al., 2007).”
BackgroundIncretin Hormones and Type 2 Diabetes—Mechanistic Insights and Therapeutic Approaches
Boer, G. A., & Holst, J. J. (2020) · Biology · doi:10.3390/biology9120473 · Cited by 153
“It has been suggested that fo lowing release from the L-ce l, GLP-1 activates GLP-1 r tr s orted to the termin in the gut or the hepatic portal bed of vagal, afferent sensory nerve fibres arising from the nodose ganglion [95,101].”
BackgroundGLP-1 based therapeutics: simultaneously combating T2DM and obesity
Heppner, K. M., & Perez-Tilve, D. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00092 · Cited by 115
“Thus, blockade of hepatic portal GLP-1R signaling causes glucose intolerance in rats, suggesting that GLP-1Rs located on nerve terminals in the hepatic portal vein contribute to the incretin action of GLP-1 (Vahl et al., 2007).”
BackgroundMechanisms controlling hormone secretion in human gut and its relevance to metabolism
Martin, A. M., Sun, E. W., & Keating, D. J. (2020) · Journal of Endocrinology · doi:10.1530/joe-19-0399 · Cited by 109
GLP-1, the Gut-Brain, and Brain-Periphery Axes
Cabou, C., & Burcelin, R. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.418 · Cited by 110
“Indeed, experimental studies on rodents in our laboratory, and from others, have shown that glucose detection is associated with GLP-1 secretion and action on peripheral receptors localized on vagal nerve fibers in the enteric area [56], which includes the hepatoportal veins [55, 57-58].”
BackgroundMu-Opioid Receptors and Dietary Protein Stimulate a Gut-Brain Neural Circuitry Limiting Food Intake
Duraffourd, C. C., Vadder, F. D., Goncalves, D., Delaere, F., Penhoat, A., Brusset, B., Rajas, F., CHASSARD, D., Duchampt, A., Stefanutti, A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.05.039 · Cited by 125
“Indeed, they compensate the CCK-initiated decrease of meal size by increasing the number of meals per day (West et al., 1984).”
Chen, Y.-T., Tsai, T.-H., Yang, C.-C., Sun, C.-K., Chang, L.-T., Chen, H.-H., Chang, C.-L., Sung, P.-H., Zhen, Y.-Y., Leu, S., et al. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-270 · Cited by 109
“, GLP1R) in the central nervous system and the peripheral autonomic nervous system has been extensively investigated in previous studies [40-45], the expression of GLP-1R in renal parenchyma has not been reported.”
BackgroundThe modulatory role of high fat feeding on gastrointestinal signals in obesity
Duca, F. A., Sakar, Y., & Covașă, M. (2013) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2013.05.005 · Cited by 127
Do we know the true mechanism of action of the DPP ‐4 inhibitors?
Andersen, E. S., Deacon, C. F., & Holst, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13018 · Cited by 107
“GLP-1 receptor expression has been demonstrated in neuronal cell bodies in the nodose ganglion by in situ hybridisation,(26) and GLP-1 receptors have been identified on neurons in the portal vein (although the specificity of the GLP-R antibodies employed in that study was uncertain).(27) In addition, numerous neurons…”
BackgroundTargeting β-Cell Mass in Type 2 Diabetes: Promise and Limitations of New Drugs Based on Incretins
Salehi, M., Aulinger, B. A., & D'Alessio, D. A. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0031 · Cited by 109
Self-citationMechanisms responsible for excess weight loss after bariatric surgery
Ionut, V., & Bergman, R. N. (2011) · Journal of Diabetes Science and Technology · doi:10.1177/193229681100500536 · Cited by 105
Ulrich-Lai, Y. M., & Ryan, K. K. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.01.020 · Cited by 104
Varin, E. M., Mulvihill, E. E., Baggio, L. L., Koehler, J. A., Cao, X., Seeley, R. J., & Drucker, D. J. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.05.055 · Cited by 104
“3374 Cell Reports 27, 3371–3384, June 11, 2019 of DPP-4 inhibitors (Mulvihill et al., 2017; Vahl et al., 2007; Varin et al., 2019; Waget et al., 2011).”
Self-citationMaida, A., Lovshin, J. A., Baggio, L. L., & Drucker, D. J. (2008) · Endocrinology · doi:10.1210/en.2008-0336 · Cited by 103
“The available evidence suggests that GLP-1R agonists are capable of increasing insulin secretion through indirect neural pathways (26, 27), and via direct activation of -cell GLPFIG.”
Backgroundvan Baak, M. A. (2008) · Physiology & Behavior · doi:10.1016/j.physbeh.2007.12.020 · Cited by 122
“GLP-1 may act through GLP-1 receptors on visceral afferent nerve terminals in the portal bed [93].”
Meal-Anticipatory Glucagon-Like Peptide-1 Secretion in Rats
Vahl, T. P., Drazen, D. L., Seeley, R. J., D'Alessio, D. A., & Woods, S. C. (2010) · Endocrinology · doi:10.1210/en.2009-1002 · Cited by 101
Self-citationTargeting the CNS to treat type 2 diabetes
Sandoval, D. A., Obici, S., & Seeley, R. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2874 · Cited by 110
“In addition, hepatic portal infusions of GLP1 antagonists have been found to reduce normal glucose toleranc”
BackgroundSelf-citationOvergaard, R. V., Hertz, C. L., Ingwersen, S. H., Navarria, A., & Drucker, D. J. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100387 · Cited by 99
Williams, D. L. (2009) · Endocrinology · doi:10.1210/en.2009-0220 · Cited by 98
“the same dose of the antagonist delivered via intrajugular infusion had no effect (13).”
Direct Autocrine Action of Insulin on β-Cells: Does It Make Physiological Sense?
Rhodes, C., White, M., Leahy, J., & Kahn, S. (2013) · Diabetes · doi:10.2337/db13-0246 · Cited by 100
“Some investigators even suggest that endogenously produced incretins may, at least in part, exert their effect on b-cells via the CNS (40,41).”
BackgroundGastaldelli, A., Gaggini, M., Daniele, G., Ciociaro, D., Cersosimo, E., Tripathy, D., Triplitt, C., Fox, P., Musi, N., DeFronzo, R., et al. (2016) · Hepatology · doi:10.1002/hep.28827 · Cited by 96
“more efficient with EX versus PLC, consistent with previous results from our group((20,21,36)) and others.((7,37,38)) EX also increased fractional HGU measured with PET (Fig.”
BackgroundResultSteinert, R. E., & Beglinger, C. (2011) · Physiology & Behavior · doi:10.1016/j.physbeh.2011.02.039 · Cited by 116
Control of insulin secretion by GLP-1
Jones, B. J., Bloom, S. R., Buenaventura, T., Tomás, A., & Rutter, G. A. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.013 · Cited by 105
Targeting the GLP-1/GLP-1R axis to treat osteoarthritis: A new opportunity?
Meurot, C., Jacques, C., Martin, C., Sudre, L., Breton, J., Rattenbach, R., Bismuth, K., & Berenbaum, F. (2022) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2022.02.001 · Cited by 94
“GLP-1R is detected in peripheral nerves of rats and mice as well as in nerve terminals of the portal vein [91].”
BackgroundDong, Y., Carty, J., Goldstein, N., He, Z., Hwang, E., Chau, D., Wallace, B., Kabahizi, A., Lieu, L., Peng, Y., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101352 · Cited by 93
Reappraising the role of the vagus nerve in GLP-1-mediated regulation of eating
Brierley, D. I., & de Lartigue, G. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15603 · Cited by 92
“GLP-1 receptors are widely distributed throughout the periphery (Bullock et al., 1996; Nakagawa et al., 2004; Vahl et al., 2007) and brain (Cork et al., 2015; Larsen et al., 1997; Merchenthaler et al., 1999).”
BackgroundHayes, M. R., Mietlicki-Baase, E. G., Kanoski, S. E., & De Jonghe, B. C. (2014) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071812-161201 · Cited by 92
“The notion that paracrine-like signaling by intestinally derived GLP-1 is the primary physiological mode of action does not discount the potential secondary role of an endocrine-mediated mechanism that involves GLP-1 entering into circulation and having action on GLP-1R expressed either in the hepatoportal bed (97, 13…”
Taher, J., Baker, C. L., Cuizon, C., Masoudpour, H., Zhang, R., Farr, S., Naples, M., Bourdon, C., Pausova, Z., & Adeli, K. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.09.005 · Cited by 90
Perspectives in GLP-1 Research: New Targets, New Receptors
Cantini, G., Mannucci, E., & Luconi, M. (2016) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2016.03.017 · Cited by 102
“The secreted hormone is rapidly inactivated by DPP-4, which generates the truncated form, GLP-1(9–36), unable to bind to the classical GLP-1R, with no action on glucose metabolism [80].”
BackgroundOral l-Arginine Stimulates GLP-1 Secretion to Improve Glucose Tolerance in Male Mice
Clemmensen, C., Smajilovic, S., Smith, E. P., Woods, S. C., Bräuner-Osborne, H., Seeley, R. J., D'Alessio, D. A., & Ryan, K. K. (2013) · Endocrinology · doi:10.1210/en.2013-1529 · Cited by 87
Self-citationGLP‐1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice
Jolivalt, C. G., Fineman, M., Deacon, C. F., Carr, R. D., & Calcutt, N. A. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01431.x · Cited by 87
“Our finding of GLP-1R protein in the peripheral nerve of rats and mice, and its localization to neurons agree with the demonstration of GLP1-R in nerve terminals of the portal vein [28] and by previous reports suggesting that GLP-1R agonists have neurotrophic and neuroprotective effects on cultures of PC12 cells and C…”
ResultManell, H., Staaf, J., Manukyan, L., Kristinsson, H., Cen, J., Stenlid, R., Ciba, I., Forslund, A. H., & Bergsten, P. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3885 · Cited by 99
Hayes, M. R., Kanoski, S. E., De Jonghe, B. C., Leichner, T. M., Alhadeff, A. L., Fortin, S. M., Arnold, M., Langhans, W., & Grill, H. J. (2011) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00356.2011 · Cited by 86
Brain functional magnetic resonance imaging response to glucose and fructose infusions in humans
Purnell, J. Q., Klopfenstein, B. A., Stevens, A. A., Havel, P. J., Adams, S. H., Dunn, T. N., Krisky, C., & Rooney, W. D. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01340.x · Cited by 85
“potentially inhibitory effects mediated by induction of insulin resistance and reduced intra-neuronal insulin signalling [29], or as a result of the fact that fructose has a higher fractional extraction rate in the liver where initially higher concentrations could activate vagal afferents that might impact signalling…”
BackgroundMcLean, B. A., Wong, C. K., Kaur, K. D., Seeley, R. J., & Drucker, D. J. (2021) · JCI Insight · doi:10.1172/jci.insight.153732 · Cited by 84
“Comparison of the effects of glucagon-like peptide-1-(1-37) and -(7-37) and glucagon on islet hormone release from isolated perfused canine and rat pancreases.”
BackgroundSelf-citation
Metadata
- Authors
- Vahl, T. P., Tauchi, M., Durler, T. S., Elfers, E. E., Fernandes, T. M., Bitner, R. D., Ellis, K. S., Woods, S. C., Seeley, R. J., Herman, J. P., & D’Alessio, D. A.
- Affiliations
- University of Cincinnati (US)
- Corresponding author
- D’Alessio, David A.
- ORCID
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2007-10-01
- Volume
- 148
- Issue
- 10
- Pages
- 4965-4973
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2128181185
- Cited by
- 318
- References
- 57
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 10 · 2023: 11 · 2022: 9 · 2021: 20 · 2020: 9 · 2019: 11 · 2018: 13 · 2017: 14 · 2016: 21 · 2015: 25 · 2014: 24 · 2013: 32 · 2012: 23
- FWCI
- 13.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Cincinnati
- National Institutes of Health (DK17844)
- National Institute of Mental Health (MH 069680)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK 54263, DK17844, R01DK054890, DK-54890, T35DK060444)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- glucagon-like peptide-1, GLP-1 receptor, glucose tolerance, portal vein, visceral afferent neurons, nodose ganglion, exendin-4, glucose homeostasis, intraportal infusion
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Animals, Blood Glucose, Cell Line, Dose-Response Relationship, Drug, Glucose, Glucose Tolerance Test, Infusions, Intravenous, Liver, Male, Nerve Endings, Nodose Ganglion, Peptides, Portal Vein, Venoms, Rats, Sprague-Dawley, Receptors, Glucagon, Glucose Intolerance, Rats, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.